SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol-13-acetate-induced neoplastic transformation

Cancer Research

Volumn 67, Issue 8, 2007, Pages 3616-3625

  Gu, Qingyang ^a   Tan, Mingjia ^a   Sun, Yi ^a,b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN; LUCIFERASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN C JUN; PROTEIN FBW 7; PROTEIN SENSITIVE TO APOPTOSIS GENE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CONSENSUS SEQUENCE; CONTROLLED STUDY; FEEDBACK SYSTEM; GENE ACTIVITY; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TARGETING; REPORTER GENE; TRANSACTIVATION; UBIQUITINATION;

BINDING SITES; CARRIER PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CLONING, MOLECULAR; CONSENSUS SEQUENCE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HELA CELLS; HUMANS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-JUN; RNA-BINDING PROTEINS; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-1; UBIQUITINS;

EID: 34248547553     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4020     Document Type: Article

References (50)

1. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-400.
2. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002;4:E131-6.
3. Angel P, Karin M. The role of Jun, Fos, and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991;1072:129-57.
4. Dhar A, Young MR, Colburn NH. The role of AP-1, NF-κB, and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Mol Cell Biochem 2002;234-5:185-93.
5. Bode AM, Dong Z. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE 2003;2003:RE2.
6. Sun Y, Oberley LW. Redox regulation of transcriptional activators. Free Radic Biol Med 1996;21:335-48.
7. Dong Z, Watts RG, Sun Y, et al. Progressive elevation of AP-1 activity during preneoplastic-to-neoplastic progression as modeled in mouse JB6 cell variants. Int J Oncol 1995;7:359-64.
8. Dong Z, Birrer MJ, Watts RG, et al. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A 1994;91:609-13.
9. Huang C, Schmid PC, Ma WY, et al. Phosphatidylinositol-3 kinase is necessary for 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and activated protein 1 activation. J Biol Chem 1997;272:4187-94.
10. Li JJ, Dong Z, Dawson MI, et al. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element. Cancer Res 1996;56:483-9.
11. Jonat C, Rahmsdorf HJ, Park KK, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990;62:1189-204.
12. Watts RG, Huang C, Young MR, et al. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation. Oncogene 1998;17:3493-8.
13. Liu Y, Ludes-Meyers J, Zhang Y, et al. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 2002;21:7680-9.
14. Bernstein LR, Bravo R, Colburn NH. 12-O-tetradecanoylphorbol-13- acetate-induced levels of AP-1 proteins: a 46-kDa protein immunoprecipitated by anti-fra-1 and induced in promotion-resistant but not promotion-sensitive JB6 cells. Mol Carcinog 1992;6:221-9.
15. Huang C, Ma WY, Dong Z. The extracellular-signal-regulated protein kinases (Erks) are required for UV-induced AP-1 activation in JB6 cells. Oncogene 1999;18:2828-35.
16. Sun Y. Induction of glutathione synthetase by 1,10-phenanthroline. FEBS Lett 1997;408:16-20.
17. Duan H, Wang Y, Aviram M, et al, SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents. Mol Cell Biol 1999;19:3145-55.
18. Swaroop M, Bian J, Aviram M, et al. Expression, purification, and biochemical characterization of SAG, a RING finger redox sensitive protein. Free Radic Biol Med 1999;27:193-202.
19. Kamura T, Koepp DM, Conrad MN, et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999;284:657-61.
20. Ohta T, Michel JJ, Schottelius AJ, et al. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell 1999;3:535-41.
21. Tan P, Fuchs SY, Chen A, et al. Recruitment of a ROC1-1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of IkBa. Mol Cell 1999;3:527-33.
22. Nateri AS, Riera-Sans L, Da Costa C, et al. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 2004;303:1374-8.
23. Wertz IE, O'Rourke KM, Zhang Z, et al. Human Deetiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science 2004;303:1371-4.
24. Dhar A, Hu J, Reeves R, et al. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene 2004;23:4466-76.
25. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997;17:6330-8.
26. Li J, Tan M, Li L, et al. SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia 2005;7:312-23.
27. Sun Y, Bian J, Wang Y, et al. Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound. Oncogene 1997;14:385-93.
28. He H, Sun Y. Ribosomal protein S27L is a direct p53 target that regulates apoptosis. Oncogene 2006 Oct 23; [Epub ahead of print].
29. Sun Y, Pommier Y, Colburn NH. Acquisition of a growth-inhibitory response to phorbol ester involves DNA damage. Cancer Res 1992;52:1907-15.
30. Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A 2002;99:6047-52.
31. Xirodimas D, Saville MK, Edling C, et al. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene 2001;20:4972-83.
32. Sun Y, Nakamura K, Wendel E, et al. Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 1993;90:2827-31.
33. Chanalaris A, Sun Y, Latchman DS, et al. SAG attenuates apoptotic cell death caused by simulated ischaemia/reoxygenation in rat cardiomyocytes. J Mol Cell Cardiol 2003;35:257-64.
34. Yang GY, Pang L, Ge HL, et al. Attenuation of ischemia-induced mouse brain injury by SAG, a redox-inducible antioxidant protein. J Cereb Blood Flow Metab 2001;21:722-33.
35. Cooper SJ, MacGowan J, Ranger-Moore J, et al. Expression of dominant negative c-jun inhibits ultraviolet B-induced squamous cell carcinoma number and size in an SKH-1 hairless mouse model. Mol Cancer Res 2003;1:848-54.
36. Dong Z, Crawford HC, Lavrovsky V, et al. A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes. Mol Carcinog 1997;19:204-12.
37. Li JJ, Cao Y, Young MR, et al. Induced expression of dominant-negative c-jun downregulates NFκB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes. Mol Carcinog 2000;29:159-69.
38. Li JJ, Rhim JS, Schlegel R, et al. Expression of dominant negative Jun inhibits elevated AP-1 and NF-κB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene 1998;16:2711-21.
39. Wei W, Jin J, Schlisio S, et al. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 2005;8:25-33.
40. Colburn NH, Former BF, Nelson KA, et al. Tumour promoter induces anchorage independence irreversibly. Nature 1979;281:589-91.
41. Sun Y, Hegamyer G, Colburn NH. Molecular cloning of five messenger RNAs differentially expressed in preneoplastic or neoplastic JB6 mouse epidermal cells: one is homologous to human tissue inhibitor of metalloproteinases-3. Cancer Res 1994;54:1139-44.
42. Karin M, Gallagher E. From JNK to pay dirt: jun kinases, their biochemistry, physiology, and clinical importance. IUBMB Life 2005;57:283-95.
43. Fang D, Kerppola TK. Ubiquitin-mediated fluorescence complementation reveals that Jun ubiquitinated by Itch/AIP4 is localized to lysosomes. Proc Natl Acad Sci U S A 2004;101:14782-7.
44. Gao M, Labuda T, Xia Y, et al. Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science 2004;306:271-5.
45. Swaroop M, Gosink M, Sun Y. SAG/ROC2/Rbx2/Hrt2, a component of SCF E3 ubiquitin ligase: genomic structure, a splicing variant, and two family pseudogenes. DNA Cell Biol 2001;20:425-34.
46. Young MR, Li JJ, Rincon M, et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci USA 1999;96:9827-32.
47. Wang X, Zinkel S, Polonsky K, et al. Transgenic studies with a keratin promoter-driven growth hormone transgene: prospects for gene therapy. Proc Natl Acad Sci U S A 1997;94:219-26.
48. Wu X, Bayle JH, Olson D, et al. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7:1126-32.
49. Sun Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic Biol Med 1990;8:583-99.
50. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-68.